Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

Locally T3/T4 recurrent nasopharyngeal carcinoma (NPC) may be salvaged by intensity modulated-radiotherapy (IMRT), but local control is not good enough and late toxicities is usually severe The aim of this phase III randomized controlled study is to address the efficacy of concurrent chemotherapy (cisplatin) with IMRT to improve local control and lower the occurrence of severe late toxicities compared with IMRT alone for locally T3/T4 recurrent NPC patients.

Inclusion criteria

• 1.Pathologically or clinically confirmed rT3/T4 locally recurrent nasopharyngeal carcinoma;

2.No evidence of distant metastasis

3.More than 1 year from the end of the first course of radiotherapy

4.Male, or female not in the phase of lactating or pregnancy

5.ECOG 0-2

6.Aged 18-70 years old

7.WBC count ≥4×109/L, neutrophile granulocyte count≥1.5×109/L, PLT count ≥100×109/L, Hb ≥9g/L

8.Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of upper normal limits

9.Written informed consort signed

Exclusion criteria

• Only regionally recurrence
• Evidence of distant metastasis
• Prior invasive malignancy; noninvasive cancers (For example, carcinoma in situ of the bladder, oral cavity, or cervix are all permissible) are permitted
• Severe, active co-morbidity
• Prior anti-tumor treatment after diagnosis of local recurrence
• MRI was not performed 3 months after the first course of radiotherapy
• Abnormal function of heart, brain and lungs, etc
• Lactation or pregnancy
• Severe nasopharyngeal mucosal necrosis at the diagnosis of local recurrence